Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | WDR5 | P61964 | 2/20 | 0.48 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | IDE | P14735 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29645275 | 1.00 | MAPT (0.48) | MAPTALDH1A1LMNAHPGDCYP2C9 | |
| Hydrochloric Acid SCHEMBL28082928 | 0.98 | MAPT (0.47) | MAPTALDH1A1LMNAHPGDCYP2C9 | |
| Hydrochloric Acid SCHEMBL2781673 | 0.98 | MAPT (0.47) | MAPTALDH1A1LMNAHPGDCYP2C9 | |
| Water SCHEMBL28093018 | 0.97 | MAPT (0.46) | MAPTALDH1A1LMNAHPGDCYP2C9 | |
| SCHEMBL8551045 | 0.92 | ALDH1A1 (0.41) | MAPTALDH1A1LMNAHPGDCYP2C9 | |
| SCHEMBL6872706 | 0.88 | MAPT (0.38) | MAPTALDH1A1LMNAHPGDCYP2C9 | |
| SCHEMBL27971566 | 0.85 | CYP2C9 (0.40) | MAPTALDH1A1LMNAHPGDCYP2C9 | |
| Hydrochloric Acid SCHEMBL6865752 | 0.85 | MAPT (0.36) | MAPTALDH1A1LMNAHPGDCYP2C9 | |
| SCHEMBL24520493 | 0.85 | MAPT (0.49) | MAPTALDH1A1LMNAHPGDCYP2C9 | |
| SCHEMBL1308045 | 0.85 | KMT2A (0.49) | MAPTALDH1A1LMNAHPGDCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114609268-B | Detection method for related substances in sodium rabeprazole bulk drug | 南京海纳医药科技股份有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-114609268-A | Method for detecting related substances in dextral rabeprazole sodium bulk drug | 南京海纳医药科技股份有限公司 | 2022-06-10 | — | — | CN | claimed |
| CN-103965166-B | Rabeprazole intermediate impurities 2-{ [4-(3-methoxy propoxy)-3-oxide of mathylpyridine-2-base] methyl sulfur } preparation method of-1H-benzimidazole | 东南大学 | 2016-08-17 | — | — | CN | claimed |
| CN-103058997-A | Synthesis method of thioether nitrogen oxides (2-{[4-(3-methoxy-propoxy)-3-methyl nitrogen-oxygen pyridine-2-group] methylmercapto}-1H-benzimidazole) | NEW DRUG DEV COMPANY LTD OF JILIN XIUZHENG PHARMACEUTICAL GROUP | 2013-04-24 | — | — | CN | claimed |
| EP-1851212-B1 | NEW PROCESS FOR SYNTHESIS OF PROTON PUMP INHIBITORS | CIPLA LTD (IN) | 2010-07-07 | — | — | EP | claimed |
| WO-2025016200-A1 | CHELATING RESIN COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海稀固科技有限公司 | 2025-01-23 | — | — | WO | disclosed |
| US-20240238264-A1 | INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF | DISARM THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238264-A1 | INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF | DISARM THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| CN-114609268-B | Detection method for related substances in sodium rabeprazole bulk drug | 南京海纳医药科技股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-115215877-B | Preparation method of Annarazole | 轩竹(北京)医药科技有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-115215877-A | Preparation method of anaprazole | 轩竹(北京)医药科技有限公司 | 2022-10-21 | — | — | CN | disclosed |
| WO-2022143610-A1 | NOVEL AMIDE PYRROLE COMPOUNDS AND USE THEREOF IN MEDICAMENTS | 广东东阳光药业有限公司 | 2022-07-07 | — | — | WO | disclosed |
| US-5998445-A | PEPTIC ULCERS | EISAI CO., LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| US-5840910-A | Pyridine derivatives having anti-ulcerative activity | ESAI CO., LTD. (JP) | 1998-11-24 | — | — | US | disclosed |
| EP-0268956-B2 | Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and a process for preparing the same | EISAI CO LTD (JP) | 1998-04-15 | — | — | EP | disclosed |
| EP-0786461-A1 | Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and a process for preparing the same | Eisai Co., Ltd. (JP) | 1997-07-30 | — | — | EP | disclosed |
| EP-0654471-A1 | Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and process for preparing the same | Eisai Co., Ltd. (JP) | 1995-05-24 | — | — | EP | disclosed |
| EP-0475456-A1 | Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and a process for preparing the same | Eisai Co., Ltd. (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-5045552-A | Pyridine derivatives having anti-ulcerative activity | EISAI CO., LTD. (JP) | 1991-09-03 | — | — | US | disclosed |
| EP-0268956-A2 | Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and a process for preparing the same | Eisai Co., Ltd. (JP) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238264-A1 | INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF | SARM1, NADK, NNMT | MAPT 242/4885ALDH1A1 1659/4885LMNA 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.